Neonc Technologies Holdings Inc. Advances in Brain Cancer Treatment
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, is making significant strides in the development of treatments for intracranial malignancies, particularly aggressive brain cancers. The company is pioneering a novel molecular technology aimed at enhancing the targeted delivery of treatments for central nervous system diseases.
Innovative Drug Delivery Methods
NeOnc is focused on developing innovative drug delivery methods that can be used in conjunction with novel drug candidates. The company’s lead products, NEO100 and NEO212, are at the forefront of this effort. NEO100 is a purified form of perillyl acid (POH) designed for intranasal delivery to brain cancer patients. This method aims to improve the efficacy and accessibility of treatment for those suffering from brain cancer.
Development of NEO212
NEO212 represents another significant advancement by NeOnc. This covalently conjugated molecule combines the chemotherapeutic drug temozolomide with perillyl alcohol. Currently, NEO212 is being developed for intranasal application, specifically targeting patients with uncontrolled brain metastases originating from peripheral tumors such as lung, breast, and skin cancers.
Financial Overview
As of August 14, 2025, NeOnc Technologies Holdings, Inc. is listed on the Nasdaq with a close price of $5.12. The company’s market capitalization stands at $98,750,000 USD. Over the past year, the stock has experienced significant volatility, reaching a 52-week high of $67.8 on October 22, 2024, and a low of $0.5112 on February 24, 2025. The price-to-earnings ratio is currently at -2.02, reflecting the company’s ongoing development phase and lack of profitability.
Focus on Health Care Sector
Operating within the health care sector, NeOnc Technologies Holdings, Inc. is dedicated to addressing the critical need for effective treatments for brain cancers. The company’s innovative approach to drug delivery and its focus on developing targeted therapies position it as a key player in the biopharmaceutical industry.
As NeOnc continues its clinical trials and development efforts, the company remains committed to advancing its lead products, NEO100 and NEO212, with the goal of providing new hope for patients battling intracranial malignancies.